Welcome to Dermbits! Watch short videos of KOLs answering your questions

See all conditionsAcneActinic KeratosisAestheticsAlopeciaAtopic DermatitisConnective Tissue DiseasesCOVID-19Cutaneous MelanomaEczemaGeneralized Pustular Psoriasis (GPP)Hair and NailsHidradenitis SuppurativaJAK InhibitorsNB-UVBPigmentary DisordersPsoriasisPsoriatic ArthritisRosaceaSkin CancerSunscreenTopical TherapiesVitiligoWarts And Molluscum

Topical Therapies

What documentation details helps support approval for ruxolitinib cream?

Featuring Alexandra Golant, MD

Topical Therapies

Can EHR templates improve access for new therapies like ruxolitinib?

Featuring Alexandra Golant, MD

Topical Therapies

What are common documentation mistakes that delay access to newer topicals?

Featuring Alexandra Golant, MD

Topical Therapies

What’s key to documenting steroid failure or intolerance clearly?

Featuring Alexandra Golant, MD

Topical Therapies

How do you talk to patients when access issues delay treatment?

Featuring Alexandra Golant, MD

Topical Therapies

What’s your top access tip for new clinicians balancing care and paperwork?

Featuring Alexandra Golant, MD

Cutaneous Melanoma

How does the MyPath Melanoma test differ from standard histopathologic evaluation?

Featuring Brent Moody, MD

Cutaneous Melanoma

When should dermatologists consider the use of MyPath Melanoma test for a suspicious lesion?

Featuring Brent Moody, MD

Cutaneous Melanoma

How should MyPath Melanoma test results be interpreted, especially when the result is not clearly benign or malignant?

Featuring Brent Moody, MD

Cutaneous Melanoma

What logistical considerations should dermatologists keep in mind when ordering MyPath Melanoma?

Featuring Brent Moody, MD

Cutaneous Melanoma

In what clinical scenarios might a dermatologist consider ordering MyPath Melanoma for a melanocytic lesion?

Featuring Brent Moody, MD

Cutaneous Melanoma

Can you describe how MyPath Melanoma adds clinical value when evaluating melanocytic lesions that are not clearly malignant?

Featuring Brent Moody, MD

Cutaneous Melanoma

How does a positive or negative MyPath Melanoma result impact your treatment recommendations?

Featuring Brent Moody, MD

Cutaneous Melanoma

What role do you see molecular diagnostics playing in the early detection and management of melanoma over the next 5 to 10 years?

Featuring Brent Moody, MD

Cutaneous Melanoma

What makes some melanocytic lesions difficult to diagnose based on histopathology alone?

Featuring Brent Moody, MD

Cutaneous Melanoma

What are the biggest challenges in managing atypical melanocytic lesions with ambiguous histology? With Dr. Moody

Featuring Brent Moody, MD

Sunscreen

What makes a sunscreen well formulated from both a clinician and patient perspective?

Featuring Heather Woolery-Lloyd, MD

Sunscreen

How do ingredients beyond UV filters, like antioxidants or moisturizers, enhance photoprotection?

Featuring Heather Woolery-Lloyd, MD

Sunscreen

How do you identify sunscreens that offer reliable broad-spectrum protection beyond SPF ratings?

Featuring Heather Woolery-Lloyd, MD

Sunscreen

What makes a sunscreen particularly effective for pigment protection or visible-light defense?

Featuring Heather Woolery-Lloyd, MD

Sunscreen

What is Helioplex technology, and how does it improve stability and UV coverage?

Featuring Heather Woolery-Lloyd, MD

Sunscreen

Why does a higher SPF still matter in real-world use?

Featuring Heather Woolery-Lloyd, MD

Sunscreen

What is your take on the role of antioxidants in photoprotection?

Featuring Heather Woolery-Lloyd, MD

Sunscreen

What are your go-to strategies for improving sunscreen adherence in daily life?

Featuring Heather Woolery-Lloyd, MD

Sunscreen

Are there any patient groups you feel are undercounseled when it comes to the risks of photodamage?

Featuring Heather Woolery-Lloyd, MD

Sunscreen

Which common medications increase photosensitivity, and how should this shape your counseling?

Featuring Heather Woolery-Lloyd, MD

Acne

How do you approach treating acne without compromising the skin barrier, especially in patients with sensitive skin?

Featuring Joshua Zeichner, MD

Acne

Why is salicylic acid a useful ingredient in acne cleansers, and how can formulation approaches improve its delivery?

Featuring Joshua Zeichner, MD

Acne

What role does the skin barrier play in acne pathophysiology, and how should it influence treatment selection?

Featuring Joshua Zeichner, MD

Acne

Are there specific ingredients or technologies that help balance acne treatment with barrier preservation?

Featuring Joshua Zeichner, MD

Acne

What are hydrophobically modified polymers, and what role do they play in cleanser tolerability?

Featuring Joshua Zeichner, MD

Acne

What role do hydrocolloidal patches play in an acne routine, and when do you typically recommend them?

Featuring Joshua Zeichner, MD

Acne

What’s the clinical significance of using 2% salicylic acid in combination with polymeric cleansing technology?

Featuring Joshua Zeichner, MD

Acne

How can dermatologists help patients pair prescription acne medications with over-the-counter products that protect the skin barrier?

Featuring Joshua Zeichner, MD

Acne

What role does patient education play in making sure over-the-counter products support rather than interfere with prescription therapies?

Featuring Joshua Zeichner, MD

Acne

What is the "retinol sandwich" method for managing acne?

Featuring Joshua Zeichner, MD

Actinic Keratosis

What are the practical advantages of prescribing the 350 mg packet of tirbanibulin over the 250 mg?

Featuring Vishal Patel, MD, FAAD, FACMS

Actinic Keratosis

In terms of a clearance timeline, what expectations should clinicians set with themselves and with patients starting tirbanibulin, especially when comparing it with therapies like 5-FU?

Featuring Vishal Patel, MD, FAAD, FACMS

Actinic Keratosis

How do you counsel patients and colleagues about the timeline of response, given that visible skin reaction may not appear immediately?

Featuring Vishal Patel, MD, FAAD, FACMS

Actinic Keratosis

When might you choose tirbanibulin over 5-FU for AK field therapy?

Featuring Vishal Patel, MD, FAAD, FACMS

Actinic Keratosis

How do you approach field therapy in actinic keratosis, and where does tirbanibulin fit into that strategy?

Featuring Vishal Patel, MD, FAAD, FACMS

Actinic Keratosis

How do you advise scheduling follow-up visits for patients on tirbanibulin, knowing pivotal trial endpoints extended to 57 days?

Featuring Vishal Patel, MD, FAAD, FACMS

Actinic Keratosis

What were the key findings of the PROAK study, and how did its results inform our understanding of tirbanibulin’s impact on patient quality of life?

Featuring Vishal Patel, MD, FAAD, FACMS

Actinic Keratosis

What is the estimated risk of progression from actinic keratosis to squamous cell carcinoma, and how does lesion count affect this risk?

Featuring Vishal Patel, MD, FAAD, FACMS

Actinic Keratosis

How can dermatologists decide between lesion-directed and field-directed therapies when treating actinic keratosis?

Featuring Vishal Patel, MD, FAAD, FACMS

Actinic Keratosis

What advancements in the understanding of actinic keratosis pathophysiology or treatment are shaping future management approaches?

Featuring Vishal Patel, MD, FAAD, FACMS

NB-UVB

Is home-based NB-UVB a challenge to prescribe for clinicians?

Featuring Jessica Kaffenberger, MD

NB-UVB

What practical steps can a dermatologist take to start prescribing a home-based NB-UVB device?

Featuring Jessica Kaffenberger, MD

NB-UVB

What are the key benefits of home-based NB-UVB devices?

Featuring Jessica Kaffenberger, MD

NB-UVB

Is home-based NB-UVB better suited for localized disease or widespread conditions?

Featuring Jessica Kaffenberger, MD

NB-UVB

Is home-based NB-UVB device setup difficult for patients?

Featuring Jessica Kaffenberger, MD

NB-UVB

How does guided dosing mode on newer devices improve safety and reduce uncertainty for both patients and dermatologists?

Featuring Jessica Kaffenberger, MD

NB-UVB

How straightforward is the prescribing and enrollment process for at-home phototherapy?

Featuring Jessica Kaffenberger, MD

NB-UVB

Why has phototherapy declined in use, and are the main barriers clinical or logistical?

Featuring Jessica Kaffenberger, MD

NB-UVB

What practical considerations should dermatologists keep in mind when setting up a patient with an at-home phototherapy unit?

Featuring Jessica Kaffenberger, MD

NB-UVB

What kind of clearance rates can be expected in psoriasis with NB-UVB phototherapy?

Featuring Jessica Kaffenberger, MD

Atopic Dermatitis

What differentiates IL-13 from IL-4 in the progression of AD?

Featuring Charlie Dunn, MD

Atopic Dermatitis

How do you identify and manage itch-dominant AD patients?

Featuring Charlie Dunn, MD

Atopic Dermatitis

How can dermatologists more effectively measure and monitor treatment success beyond traditional scaling/scoring tools?

Featuring Charlie Dunn, MD

Atopic Dermatitis

What role does proactive vs reactive therapy play in maintaining long-term disease control in AD?

Featuring Charlie Dunn, MD

Atopic Dermatitis

What factors can help dermatologists determine which cytokine pathway to target when selecting a therapy for AD?

Featuring Charlie Dunn, MD

Atopic Dermatitis

What are the long-term impacts of early-onset AD on child development and overall health?

Featuring Charlie Dunn, MD

Atopic Dermatitis

Should patients with moderate AD by treated with systemic therapies earlier in disease progression?

Featuring Charlie Dunn, MD

Atopic Dermatitis

How can dermatologists identify and manage treatment resistance in patients with AD?

Featuring Charlie Dunn, MD

Atopic Dermatitis

What are the most effective ways to communicate realistic treatment expectations to patients with AD?

Featuring Charlie Dunn, MD

Atopic Dermatitis

What challenges exist in assessing AD in patients with skin of color, and how can they be addressed?

Featuring Charlie Dunn, MD

Atopic Dermatitis

Do patients need to demonstrate inadequate response to topical therapies before initiating lebrikizumab?

Featuring James Del Rosso, DO

Atopic Dermatitis

Why is systemic therapy for atopic dermatitis still underutilized, despite the availability of newer targeted options?

Featuring James Del Rosso, DO

Atopic Dermatitis

How can dermatologists improve diagnostic accuracy for AD in skin of color?

Featuring James Del Rosso, DO

Atopic Dermatitis

What clinical features define an ideal patient profile for starting lebrikizumab?

Featuring James Del Rosso, DO

Atopic Dermatitis

Are most patients beginning lebrikizumab already previously treated with another biologic, or are some biologic-naïve?

Featuring James Del Rosso, DO

Atopic Dermatitis

Should dermatologists adjust lebrikizumab dosing in patients who experience flares during maintenance therapy?

Featuring James Del Rosso, DO

Atopic Dermatitis

What insights did the ADhere study provide about combining lebrikizumab with topical corticosteroids?

Featuring James Del Rosso, DO

Atopic Dermatitis

What results were seen in the clinical trials for lebrikizumab regarding itch reduction?

Featuring James Del Rosso, DO

Atopic Dermatitis

What laboratory monitoring, if any, is recommended for patients starting and continuing on lebrikizumab?

Featuring James Del Rosso, DO

Atopic Dermatitis

What outcomes have been observed with monthly maintenance dosing of lebrikizumab?

Featuring James Del Rosso, DO

Atopic Dermatitis

How should dermatologists approach patients with AD who appear “mild to moderate” clinically but have significant quality-of-life impairment?

Featuring James Del Rosso, DO

Atopic Dermatitis

What were the key findings of the ADapt trial, which studied patients switching to lebrikizumab after dupilumab treatment?

Featuring James Del Rosso, DO

Eczema

How is chronic hand eczema defined clinically, and how does it differ from atopic dermatitis?

Featuring Brad Glick, DO, MPH

Eczema

What are the major subtypes of CHE, and how can they be differentiated in clinical practice?

Featuring Brad Glick, DO, MPH

Eczema

When should dermatologists consider patch testing in patients with chronic hand eczema?

Featuring Brad Glick, DO, MPH

Eczema

What is the mechanism of action of delgocitinib cream, and how is it relevant to CHE pathophysiology?

Featuring Brad Glick, DO, MPH

Eczema

How does delgocitinib differ mechanistically from other topical therapies used for CHE?

Featuring Brad Glick, DO, MPH

Eczema

How quickly can patients with CHE expect to see improvement in skin clearance with delgocitinib cream?

Featuring Brad Glick, DO, MPH

Eczema

What is known about the durability of response of delgocitinib cream for CHE after treatment discontinuation?

Featuring Brad Glick, DO, MPH

Eczema

Does delgocitinib cream carry a boxed warning, and are there any major safety concerns clinicians should be aware of?

Featuring Brad Glick, DO, MPH

Eczema

Is routine lab monitoring required for patients on delgocitinib cream?

Featuring Brad Glick, DO, MPH

Eczema

Can delgocitinib cream for CHE be used on a continuous or as-needed basis depending on flare patterns?

Featuring Brad Glick, DO, MPH

Cutaneous Melanoma

What is the MyPath Melanoma test, and how does it work?

Featuring Alexander Witkowski, MD, PhD

Cutaneous Melanoma

What types of melanocytic lesions is the MyPath test best suited for?

Featuring Alexander Witkowski, MD, PhD

Cutaneous Melanoma

What is the difference between the MyPath Melanoma test and the DecisionDx-Melanoma test?

Featuring Alexander Witkowski, MD, PhD

Cutaneous Melanoma

What is the turnaround time for results from the MyPath Melanoma test, and how are results reported?

Featuring Alexander Witkowski, MD, PhD

Cutaneous Melanoma

Can I order the MyPath Melanoma test on a lesion that has been previously biopsied, or does it need to be planned in advance?

Featuring Alexander Witkowski, MD, PhD

Cutaneous Melanoma

Is the MyPath Melanoma test typically covered by insurance, and what should I tell patients about potential out-of-pocket costs?

Featuring Alexander Witkowski, MD, PhD

Cutaneous Melanoma

How do you incorporate MyPath results when there is histologic discordance or when pathology is borderline?

Featuring Alexander Witkowski, MD, PhD

Cutaneous Melanoma

What are your thoughts on a dermatologist ordering MyPath vs a dermatopathologist?

Featuring Alexander Witkowski, MD, PhD

Cutaneous Melanoma

How can molecular diagnostics like MyPath reduce overtreatment in certain patients?

Featuring Alexander Witkowski, MD, PhD

Cutaneous Melanoma

How do you typically approach long-term monitoring for patients with a history of severely atypical nevi or dysplastic nevi?

Featuring Alexander Witkowski, MD, PhD

Cutaneous Melanoma

What are the limitations of GEP testing in melanoma diagnosis?

Featuring Alexander Witkowski, MD, PhD

Cutaneous Melanoma

Are GEP tests meant to replace or supplement traditional pathology for melanoma?

Featuring Alexander Witkowski, MD, PhD

Cutaneous Melanoma

What are the biggest challenges in managing atypical melanocytic lesions with ambiguous histology?

Featuring Alexander Witkowski, MD, PhD

Atopic Dermatitis

How should dermatologists evaluate whether lebrikizumab is a better option than dupilumab for a given patient?

Featuring Pearl Kwong, MD

Atopic Dermatitis

Can lebrikizumab be considered for patients with mild atopic dermatitis, or is it primarily for moderate-to-severe cases?

Featuring Pearl Kwong, MD

Atopic Dermatitis

Is there flexibility in the dosing schedule for lebrikizumab to accommodate individual patient needs?

Featuring Pearl Kwong, MD

Atopic Dermatitis

What is lebrikizumab's safety profile?

Featuring Pearl Kwong, MD

Atopic Dermatitis

How does lebrikizumab compare to JAK inhibitors in terms of safety and efficacy for patients with atopic dermatitis?

Featuring Pearl Kwong, MD

Atopic Dermatitis

What clinical factors should guide dermatologists in selecting lebrikizumab over dupilumab or tralokinumab?

Featuring Pearl Kwong, MD

Atopic Dermatitis

What are the most important patient education points you should counsel your patients on when initiating treatment with lebrikizumab? With Dr. Kwong

Featuring Pearl Kwong, MD

Atopic Dermatitis

What role does shared decision-making play in improving AD outcomes, and how can it be implemented in practice?

Featuring Pearl Kwong, MD

Atopic Dermatitis

What are some limitations of traditional scoring/scaling systems in assessing AD severity?

Featuring Pearl Kwong, MD

Atopic Dermatitis

How can dermatologists work with allergists to manage patients with atopic dermatitis and significant environmental or food allergies?

Featuring Pearl Kwong, MD

Skin Cancer

What is the i31-SLNB score, and how does it improve melanoma risk stratification?

Featuring Jason Rizzo, MD, PhD

Skin Cancer

What are the key thresholds or risk categories within the i31-SLNB score?

Featuring Jason Rizzo, MD, PhD

Skin Cancer

In what types or stages of melanoma is the i31-SLNB score most clinically useful?

Featuring Jason Rizzo, MD, PhD

Skin Cancer

How does the i31-SLNB score impact the decision to refer a patient for sentinel lymph node biopsy?

Featuring Jason Rizzo, MD, PhD

Skin Cancer

What are common patient questions or concerns about this type of genomic testing?

Featuring Jason Rizzo, MD, PhD

Skin Cancer

What recent data supports the utility of the i31-SLNB score in guiding SLNB decisions?

Featuring Jason Rizzo, MD, PhD

Skin Cancer

How has the 31-GEP test report evolved?

Featuring Jason Rizzo, MD, PhD

Skin Cancer

What are some of the barriers to adopting the i31-SLNB score in community dermatology practices?

Featuring Jason Rizzo, MD, PhD

Skin Cancer

What is the long-term vision for GEP-guided melanoma staging?

Featuring Jason Rizzo, MD, PhD

Skin Cancer

What steps can be taken to ensure broader access to genomic staging tools like i31-SLNB?

Featuring Jason Rizzo, MD, PhD

Vitiligo

Is there a limit on body surface area that ruxolitinib can be applied to for vitiligo?

Featuring Amy McMichael, MD

Vitiligo

Can ruxolitinib be used as a maintenance therapy in patients with vitiligo once repigmentation has been achieved?

Featuring Amy McMichael, MD

Vitiligo

Can ruxolitinib for vitiligo be used with therapeutic biologics?

Featuring Amy McMichael, MD

Vitiligo

How do you stress the importance of adherence to patients taking ruxolitinib for vitiligo?

Featuring Amy McMichael, MD

Vitiligo

How should dermatologists approach conversations about partial vs complete repigmentation for patients on ruxolitinib for vitiligo?

Featuring Amy McMichael, MD

Vitiligo

How should dermatologists manage patients reporting skin sensitivity while on ruxolitinib for vitiligo?

Featuring Amy McMichael, MD

Vitiligo

What are some tips for successful prior authorization for patients recommended for ruxolitinib for vitiligo?

Featuring Amy McMichael, MD

Vitiligo

What are the most common causes of drug-induced vitiligo?

Featuring Amy McMichael, MD

Vitiligo

Can vitiligo spontaneously resolve?

Featuring Amy McMichael, MD

Vitiligo

How can dermatologists integrate a multidisciplinary approach in patient care to address the diverse aspects of vitiligo?

Featuring Amy McMichael, MD

Acne

How does the narrow-spectrum activity of sarecycline impact its efficacy and safety in acne?

Featuring Christopher Bunick, MD, PhD

Acne

How effective is sarecycline for managing truncal acne?

Featuring Christopher Bunick, MD, PhD

Acne

Is sarecycline an appropriate option for pediatric and preteen patients with acne?

Featuring Christopher Bunick, MD, PhD

Acne

What are the benefits of sarecycline’s once-daily dosing compared to other antibiotics?

Featuring Christopher Bunick, MD, PhD

Acne

Can sarecycline be combined with topical treatments or other systemic therapies?

Featuring Christopher Bunick, MD, PhD

Acne

How does sarecycline fit into the current guidelines for acne management and antibiotic stewardship?

Featuring Christopher Bunick, MD, PhD

Acne

Are there ongoing studies or emerging insights into additional indications for sarecycline beyond acne?

Featuring Christopher Bunick, MD, PhD

Acne

What are the latest insights into the impact of hormonal fluctuations on acne severity?

Featuring Christopher Bunick, MD, PhD

Acne

How should dermatologists determine when to escalate from topical to systemic acne treatments?

Featuring Christopher Bunick, MD, PhD

Acne

How should acne treatments be adjusted for patients with sensitive or atopic skin?

Featuring Christopher Bunick, MD, PhD

Atopic Dermatitis

What is the role of the IL-13 pathway in AD pathogenesis and treatment?

Featuring Dawn Merritt, DO

Atopic Dermatitis

What is the relationship between itch improvement and overall AD control?

Featuring Dawn Merritt, DO

Atopic Dermatitis

What is the role of IL-13 in driving itch in AD?

Featuring Dawn Merritt, DO

Atopic Dermatitis

How can dermatologists define a patient with moderate AD, and what clinical markers guide this classification?

Featuring Dawn Merritt, DO

Atopic Dermatitis

Why aren’t more patients with moderate AD treated with advanced systemic therapies?

Featuring Dawn Merritt, DO

Atopic Dermatitis

How can dermatologists decide when to escalate to a systemic therapy for a patient with AD?

Featuring Dawn Merritt, DO

Atopic Dermatitis

What are the expected timelines for clinical improvement when initiating systemic therapies for AD?

Featuring Dawn Merritt, DO

Atopic Dermatitis

How do you educate patients about the chronic nature of AD to improve adherence?

Featuring Dawn Merritt, DO

Atopic Dermatitis

How do you counsel patients on symptom fluctuation and reinforce the importance of treatment adherence?

Featuring Dawn Merritt, DO

Atopic Dermatitis

How can dermatologists effectively recognize and manage mental health comorbidities in patients with AD?

Featuring Dawn Merritt, DO

Vitiligo

What conditions should be considered in the clinical differential diagnosis of vitiligo?

Featuring Nicholas Brownstone, MD

Vitiligo

What is the epidemiology of vitiligo?

Featuring Nicholas Brownstone, MD

Vitiligo

What is the role of inflammation in the pathogenesis of vitiligo?

Featuring Nicholas Brownstone, MD

Vitiligo

How can patients with vitiligo get involved in support groups?

Featuring Nicholas Brownstone, MD

Vitiligo

What is the Koebner phenomenon in vitiligo?

Featuring Nicholas Brownstone, MD

Vitiligo

What are some dermatologic syndromes that present with vitiligo?

Featuring Nicholas Brownstone, MD

Vitiligo

What are some rare clinical subtypes of vitiligo?

Featuring Nicholas Brownstone, MD

Vitiligo

How can vitiligo be distinguished from contact leukoderma?

Featuring Nicholas Brownstone, MD

Vitiligo

Is it common for patients with vitiligo to have other autoimmune diseases?

Featuring Nicholas Brownstone, MD

Vitiligo

Can vitiligo be treated with surgical intervention?

Featuring Nicholas Brownstone, MD

Vitiligo

Can ruxolitinib be used as a maintenance therapy in patients with vitiligo once repigmentation has been achieved?

Featuring Seemal Desai, MD

Vitiligo

Are there any recommendations for tapering ruxolitinib for vitiligo to minimize rebound depigmentation?

Featuring Seemal Desai, MD

Vitiligo

Do topical calcineurin inhibitors and corticosteroids have a role as adjunctive therapy with ruxolitinib, or should they be replaced entirely?

Featuring Seemal Desai, MD

Vitiligo

Can ruxolitinib for vitiligo be used with therapeutic biologics?

Featuring Seemal Desai, MD

Vitiligo

How do comorbidities affect the decision to prescribe ruxolitinib for vitiligo?

Featuring Seemal Desai, MD

Vitiligo

Are there any benefits to using ruxolitinib in combination with narrowband UVB for vitiligo?

Featuring Seemal Desai, MD

Vitiligo

How does repigmentation progress over time with ruxolitinib treatment?

Featuring Seemal Desai, MD

Vitiligo

Are there any emerging technologies or diagnostic tools that can enhance the early detection of vitiligo?

Featuring Seemal Desai, MD

Vitiligo

What is the outlook on microneedling for vitiligo?

Featuring Seemal Desai, MD

Vitiligo

What are some of the dermoscopic features of vitiligo?

Featuring Seemal Desai, MD

Atopic Dermatitis

Is there any long-term safety data available for lebrikizumab?

Featuring Alexandra Golant, MD

Atopic Dermatitis

How long should patients remain on lebrikizumab to achieve optimal long-term control of their atopic dermatitis symptoms?

Featuring Alexandra Golant, MD

Atopic Dermatitis

Is lebrikizumab appropriate for patients who have failed other biologics?

Featuring Alexandra Golant, MD

Atopic Dermatitis

Did any patients in clinical trials for lebrikizumab achieve EASI90?

Featuring Alexandra Golant, MD

Atopic Dermatitis

How does lebrikizumab fit into proactive vs reactive AD treatment approaches?

Featuring Alexandra Golant, MD

Atopic Dermatitis

Should lebrikizumab be used as monotherapy or can it be combined with other treatments?

Featuring Alexandra Golant, MD

Atopic Dermatitis

What are the practical considerations for incorporating lebrikizumab into long-term treatment plans?

Featuring Alexandra Golant, MD

Atopic Dermatitis

What is the importance of early intervention in preventing disease progression in atopic dermatitis?

Featuring Alexandra Golant, MD

Atopic Dermatitis

How should dermatologists sequence topical and systemic treatments in patients with refractory atopic dermatitis?

Featuring Alexandra Golant, MD

Atopic Dermatitis

How can dermatologists tailor treatment plans for patients with frequent infections related to atopic dermatitis?

Featuring Alexandra Golant, MD

Vitiligo

Why is ruxolitinib uniquely suited to treat vitiligo compared to other JAK inhibitors?

Featuring Neal Bhatia, MD

Vitiligo

How does ruxolitinib compare to topical corticosteroids and topical calcineurin inhibitors for vitiligo?

Featuring Neal Bhatia, MD

Vitiligo

Does the efficacy of ruxolitinib for vitiligo vary across Fitzpatrick skin types?

Featuring Neal Bhatia, MD

Vitiligo

What rate of facial repigmentation was seen in clinical trials for ruxolitinib in patients with vitiligo?

Featuring Neal Bhatia, MD

Vitiligo

How frequently should dermatologists follow up with patients taking ruxolitinib for vitiligo?

Featuring Neal Bhatia, MD

Vitiligo

What strategies can dermatologists use to improve patient adherence to ruxolitinib for vitiligo?

Featuring Neal Bhatia, MD

Vitiligo

Is there a risk of systemic absorption with ruxolitinib for vitiligo?

Featuring Neal Bhatia, MD

Vitiligo

What are some therapies that are currently in the pipeline for the treatment of vitiligo?

Featuring Neal Bhatia, MD

Vitiligo

What are the emerging therapies or treatment modalities being investigated for vitiligo?

Featuring Neal Bhatia, MD

Vitiligo

How can dermatologists support patients in managing the psychological impacts of living with vitiligo?

Featuring Neal Bhatia, MD

Cutaneous Melanoma

What is the i31-SLNB algorithm, and how can it enhance SLNB guidance in melanoma management?

Featuring Harrison Nguyen, MD

Cutaneous Melanoma

What is the DecisionDx Melanoma test, and how does it work?

Featuring Harrison Nguyen, MD

Cutaneous Melanoma

What are the key clinical questions the DecisionDx Melanoma test helps answer?

Featuring Harrison Nguyen, MD

Cutaneous Melanoma

Is the DecisionDx test appropriate for all patients with melanoma, or are there specific eligibility criteria?

Featuring Harrison Nguyen, MD

Cutaneous Melanoma

How can the DecisionDx Melanoma test contribute to improved survival outcomes for patients?

Featuring Harrison Nguyen, MD

Cutaneous Melanoma

How does the DecisionDx Melanoma test compare to other GEP tests, such as the CP-GEP test, in clinical accuracy and utility?

Featuring Harrison Nguyen, MD

Cutaneous Melanoma

How can dermatologists explain the DecisionDx Melanoma test and its significance to their patients?

Featuring Harrison Nguyen, MD

Cutaneous Melanoma

What are the challenges in diagnosing melanoma in patients with skin of color, and how can they be addressed?

Featuring Harrison Nguyen, MD

Cutaneous Melanoma

How do you approach biopsying suspicious lesions, and what techniques yield the best diagnostic outcomes?

Featuring Harrison Nguyen, MD

Cutaneous Melanoma

What clinical and pathological features most significantly impact melanoma prognosis?

Featuring Harrison Nguyen, MD

Actinic Keratosis

With tirbanibulin ointment now approved for treating a larger surface area up to 100 cm², how does this improve treatment flexibility for patients and providers?

Featuring Theodore Rosen, MD

Actinic Keratosis

Can tirbanibulin ointment be safely and effectively used for actinic keratosis on the full face?

Featuring Theodore Rosen, MD

Actinic Keratosis

How does the safety of tirbanibulin ointment when treating larger surface areas compare to the safety observed in the original clinical trials?

Featuring Theodore Rosen, MD

Actinic Keratosis

Are skin reactions common with tirbanibulin ointment, and when do they typically peak?

Featuring Theodore Rosen, MD

Actinic Keratosis

What strategies can dermatologists use to manage common side effects associated with tirbanibulin ointment?

Featuring Theodore Rosen, MD

Actinic Keratosis

How does tirbanibulin ointment's efficacy compare with other field-directed therapies for actinic keratosis?

Featuring Theodore Rosen, MD

Actinic Keratosis

What is the recommended dosing regimen for tirbanibulin ointment, and how does it differ from other field therapies?

Featuring Theodore Rosen, MD

Actinic Keratosis

What are the key risk factors for developing actinic keratosis, and how can dermatologists identify high-risk patients?

Featuring Theodore Rosen, MD

Actinic Keratosis

Why is it important to address actinic keratosis as a chronic condition rather than isolated lesions?

Featuring Theodore Rosen, MD

Actinic Keratosis

What are the most effective strategies for preventing actinic keratosis in at-risk populations?

Featuring Theodore Rosen, MD

Atopic Dermatitis

What were the key results from the ADORING 1 and ADORING 2 pivotal trials for tapinarof in terms of efficacy?

Featuring Joshua Zeichner, MD

Atopic Dermatitis

How effective is tapinarof in reducing itch for patients with atopic dermatitis?

Featuring Joshua Zeichner, MD

Atopic Dermatitis

What is the safety profile of tapinarof for atopic dermatitis?

Featuring Joshua Zeichner, MD

Atopic Dermatitis

What are the most common adverse effects observed with tapinarof for atopic dermatitis?

Featuring Joshua Zeichner, MD

Atopic Dermatitis

How does tapinarof’s unique mechanism of action impact the disease course of atopic dermatitis?

Featuring Joshua Zeichner, MD

Atopic Dermatitis

What role does tapinarof play in restoring skin barrier function in atopic dermatitis?

Featuring Joshua Zeichner, MD

Atopic Dermatitis

How does tapinarof differ mechanistically from other topical treatments for atopic dermatitis?

Featuring Joshua Zeichner, MD

Atopic Dermatitis

What is your approach when counseling a patient who has experienced multiple AD treatment failures?

Featuring Joshua Zeichner, MD

Atopic Dermatitis

How do you counsel patients with atopic dermatitis on reducing the risk of skin infection?

Featuring Joshua Zeichner, MD

Atopic Dermatitis

How does skin barrier dysfunction contribute to the pathogenesis of atopic dermatitis?

Featuring Joshua Zeichner, MD

Atopic Dermatitis

What considerations should be taken when transitioning a patient from another biologic to lebrikizumab?

Featuring Gabriela Maloney, DO

Atopic Dermatitis

How well does lebrikizumab maintain remission in patients who have achieved clear or almost clear skin?

Featuring Gabriela Maloney, DO

Atopic Dermatitis

In what ways can dermatologists customize treatment plans when prescribing lebrikizumab?

Featuring Gabriela Maloney, DO

Atopic Dermatitis

How does the skin microbiome differ in patients with atopic dermatitis compared to healthy controls?

Featuring Gabriela Maloney, DO

Atopic Dermatitis

Is there any clinical evidence to support the role of probiotics and prebiotics in managing atopic dermatitis?

Featuring Gabriela Maloney, DO

Atopic Dermatitis

What are the latest updates on the role of IL-4 and IL-13 in the pathogenesis of atopic dermatitis?

Featuring Gabriela Maloney, DO

Alopecia

Does ritlecitinib interact with vaccines, and should vaccination schedules be adjusted for patients on ritlecitinib?

Featuring Glynis Ablon, MD

Alopecia

What impact does ritlecitinib’s dual inhibition of JAK and TEC pathways have on the immune response in alopecia areata?

Featuring Glynis Ablon, MD

Alopecia

How important is patient adherence when using ritlecitinib, and how can dermatologists encourage it?

Featuring Glynis Ablon, MD

Alopecia

What level of efficacy is seen in adolescent patients vs the overall population of patients on ritlecitinib?

Featuring Glynis Ablon, MD

Alopecia

What should patients do if they miss a dose of ritlecitinib?

Featuring Glynis Ablon, MD

Alopecia

What ongoing monitoring is recommended for patients taking ritlecitinib?

Featuring Glynis Ablon, MD

Alopecia

What are the most common lab abnormalities observed in patients with ritlecitinib?

Featuring Glynis Ablon, MD

Alopecia

How often does alopecia areata present in conjunction with nail changes, and how can this aid diagnosis?

Featuring Glynis Ablon, MD

Alopecia

What are the key points for educating patients about alopecia areata and its management?

Featuring Glynis Ablon, MD

Alopecia

What psychological support or resources can be provided to patients with alopecia areata?

Featuring Glynis Ablon, MD

Atopic Dermatitis

How does lebrikizumab perform in treating difficult-to-manage areas like the face and hands in atopic dermatitis?

Featuring Raj Chovatiya, MD, PhD, MSCI

Atopic Dermatitis

Who is a good candidate for lebrikizumab?

Featuring Raj Chovatiya, MD, PhD, MSCI

Atopic Dermatitis

What is the dosing regimen for lebrikizumab?

Featuring Raj Chovatiya, MD, PhD, MSCI

Atopic Dermatitis

What is the safety profile of lebrikizumab?

Featuring Raj Chovatiya, MD, PhD, MSCI

Atopic Dermatitis

How does lebrikizumab impact the quality of life in patients with moderate to severe atopic dermatitis?

Featuring Raj Chovatiya, MD, PhD, MSCI

Atopic Dermatitis

Should lebrikizumab be used as monotherapy, or can it be combined with other treatments?

Featuring Raj Chovatiya, MD, PhD, MSCI

Atopic Dermatitis

What are the most important patient education points you should counsel your patients on when initiating treatment with lebrikizumab?

Featuring Raj Chovatiya, MD, PhD, MSCI

Atopic Dermatitis

What are the criteria for assessing the severity of atopic dermatitis, and how does this influence treatment decisions?

Featuring Raj Chovatiya, MD, PhD, MSCI

Atopic Dermatitis

What are the best strategies for treating atopic dermatitis in sensitive areas, such as the face or eyelids?

Featuring Raj Chovatiya, MD, PhD, MSCI

Atopic Dermatitis

What are the key considerations for using systemic corticosteroids in severe cases of atopic dermatitis?

Featuring Raj Chovatiya, MD, PhD, MSCI

Alopecia

How do you manage expectations for patients beginning treatment with ritlecitinib?

Featuring Brittany Craiglow, MD

Alopecia

What specific patient populations benefit the most from ritlecitinib treatment?

Featuring Brittany Craiglow, MD

Alopecia

Can ritlecitinib be used in all subtypes of alopecia areata?

Featuring Brittany Craiglow, MD

Alopecia

What is the recommended duration of treatment with ritlecitinib for alopecia areata?

Featuring Brittany Craiglow, MD

Alopecia

Can ritlecitinib be used as monotherapy, or can it be combined with other therapies for optimal results?

Featuring Brittany Craiglow, MD

Alopecia

What is the role of ritlecitinib in maintenance therapy for patients with alopecia areata who have achieved hair regrowth?

Featuring Brittany Craiglow, MD

Alopecia

How does ritlecitinib compare to topical treatments for alopecia areata?

Featuring Brittany Craiglow, MD

Alopecia

Are there any environmental factors that can trigger or exacerbate alopecia areata?

Featuring Brittany Craiglow, MD

Alopecia

How do you address the emotional impact of alopecia areata on patients, particularly younger individuals?

Featuring Brittany Craiglow, MD

Alopecia

How does the severity of alopecia areata influence treatment decisions?

Featuring Brittany Craiglow, MD

Atopic Dermatitis

How should dermatologists manage missed doses of lebrikizumab with patients?

Featuring Mona Shahriari, MD

Atopic Dermatitis

What are the most common adverse effects observed with lebrikizumab?

Featuring Mona Shahriari, MD

Atopic Dermatitis

Are there any specific monitoring parameters that dermatologists should follow during treatment with lebrikizumab?

Featuring Mona Shahriari, MD

Atopic Dermatitis

How quickly can patients expect to see improvement in their AD symptoms with lebrikizumab?

Featuring Mona Shahriari, MD

Atopic Dermatitis

What can patients with atopic dermatitis expect in terms of long-term efficacy and sustained symptom control with lebrikizumab treatment?

Featuring Mona Shahriari, MD

Atopic Dermatitis

In what ways can dermatologists customize treatment plans when prescribing lebrikizumab?

Featuring Mona Shahriari, MD

Atopic Dermatitis

How can dermatologists effectively position lebrikizumab as a treatment option to patients with atopic dermatitis, considering the variety of other available therapies?

Featuring Mona Shahriari, MD

Atopic Dermatitis

How should dermatologists manage atopic dermatitis during pregnancy and breastfeeding?

Featuring Mona Shahriari, MD

Atopic Dermatitis

How should dermatologists approach itch management in patients with severe pruritus due to atopic dermatitis?

Featuring Mona Shahriari, MD

Psoriasis

Are there specific patient populations who are at higher risk for adverse effects from ixekizumab?

Featuring Joel Gelfand, MD, MSCE, FAAD

Psoriasis

What are the considerations for using ixekizumab in patients with a history of serious infections?

Featuring Joel Gelfand, MD, MSCE, FAAD

Psoriasis

Does patient weight impact the dosing and efficacy of ixekizumab?

Featuring Joel Gelfand, MD, MSCE, FAAD

Psoriasis

What strategies can be used to taper ixekizumab in patients with sustained remission?

Featuring Joel Gelfand, MD, MSCE, FAAD

Psoriasis

Can ixekizumab therapy lead to sustained remission or disease modification in patients with psoriasis?

Featuring Joel Gelfand, MD, MSCE, FAAD

Psoriasis

Should ixekizumab be used as a monotherapy, or can it be used concomitantly with other therapies?

Featuring Joel Gelfand, MD, MSCE, FAAD

Psoriasis

Are there any special considerations for transitioning patients with psoriasis from other biologic agents to ixekizumab?

Featuring Joel Gelfand, MD, MSCE, FAAD

Psoriasis

What factors contribute to the progression from mild to severe psoriasis?

Featuring Joel Gelfand, MD, MSCE, FAAD

Psoriasis

How can early intervention impact the long-term course of psoriasis?

Featuring Joel Gelfand, MD, MSCE, FAAD

Psoriasis

How can dermatologists encourage a holistic approach to psoriasis treatment, including lifestyle modifications and mental health support?

Featuring Joel Gelfand, MD, MSCE, FAAD

Psoriasis

How does ixekizumab impact cardiovascular risk factors in patients with psoriasis?

Featuring Tina Bhutani, MD, MAS

Psoriasis

What are the long-term outcomes of ixekizumab therapy in terms of durability of response and maintenance of skin clearance?

Featuring Tina Bhutani, MD, MAS

Psoriasis

How does ixekizumab influence the risk of infections in patients with psoriasis?

Featuring Tina Bhutani, MD, MAS

Psoriasis

Is there any benefit to extending the dosing interval of ixekizumab in patients with stable psoriasis?

Featuring Tina Bhutani, MD, MAS

Psoriasis

Is there any evidence to suggest ixekizumab is more effective in certain psoriasis phenotypes or patient subgroups?

Featuring Tina Bhutani, MD, MAS

Psoriasis

What lifestyle modifications should be recommended to patients receiving ixekizumab?

Featuring Tina Bhutani, MD, MAS

Psoriasis

What is the recommended monitoring for patients with psoriasis receiving ixekizumab?

Featuring Tina Bhutani, MD, MAS

Psoriasis

What is the role of biopsy in confirming a diagnosis of psoriasis?

Featuring Tina Bhutani, MD, MAS

Psoriasis

What role do patient preferences play in selecting a psoriasis treatment regimen?

Featuring Tina Bhutani, MD, MAS

Psoriasis

How do you address patient concerns about the long-term use of biologics?

Featuring Tina Bhutani, MD, MAS

Alopecia

Can ritlecitinib be used in combination with topical treatments for alopecia areata?

Featuring E. James Song, MD, FAAD

Alopecia

Are there any notable drug interactions seen with ritlecitinib?

Featuring E. James Song, MD, FAAD

Alopecia

Can ritlecitinib be used in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants?

Featuring E. James Song, MD, FAAD

Alopecia

What is the mechanism of action of ritlecitinib?

Featuring E. James Song, MD, FAAD

Alopecia

Who is the ideal patient for ritlecitinib, and are there any notable exclusions?

Featuring E. James Song, MD, FAAD

Alopecia

What was the primary endpoint of the ALLEGRO-2b/3 trial for ritlecitinib?

Featuring E. James Song, MD, FAAD

Alopecia

What is the recommended dosing regimen for ritlecitinib?

Featuring E. James Song, MD, FAAD

Alopecia

What is your approach for managing nonresponders or partial responders to ritlecitinib in patients with alopecia areata?

Featuring E. James Song, MD, FAAD

Alopecia

Can alopecia areata present with atypical or unusual clinical features?

Featuring E. James Song, MD, FAAD

Alopecia

What is the significance of immune privilege in the pathogenesis of alopecia areata?

Featuring E. James Song, MD, FAAD

Alopecia

What is the likelihood of spontaneous hair regrowth in patients with alopecia areata?

Featuring E. James Song, MD, FAAD

Alopecia

Should baricitinib be considered as a first-line therapy for alopecia areata?

Featuring Karan Lal, DO, MS, FAAD

Alopecia

How does the safety profile of baricitinib compare to systemic corticosteroids in the treatment of alopecia areata?

Featuring Karan Lal, DO, MS, FAAD

Alopecia

Should therapy be stopped in patients who experience infectious events while on baricitinib?

Featuring Karan Lal, DO, MS, FAAD

Alopecia

How do you manage expectations for patients beginning treatment with baricitinib?

Featuring Karan Lal, DO, MS, FAAD

Alopecia

Are there any specific counseling points that dermatologists should discuss with patients before starting baricitinib therapy for alopecia areata?

Featuring Karan Lal, DO, MS, FAAD

Alopecia

What is the recommended approach for tapering or discontinuing baricitinib therapy in patients with alopecia areata who have achieved remission?

Featuring Karan Lal, DO, MS, FAAD

Alopecia

Can baricitinib be used in different subtypes of alopecia areata?

Featuring Karan Lal, DO, MS, FAAD

Alopecia

How does the distribution pattern of hair loss influence treatment decisions in alopecia areata?

Featuring Karan Lal, DO, MS, FAAD

Alopecia

What is the role of phototherapy in the treatment of alopecia areata?

Featuring Karan Lal, DO, MS, FAAD

Alopecia

How do you approach treatment in patients with primary cicatricial alopecia?

Featuring Karan Lal, DO, MS, FAAD

Atopic Dermatitis

What is the mechanism of action of lebrikizumab?

Featuring Peter Lio, MD

Atopic Dermatitis

What differentiates lebrikizumab from other IL-13 inhibitors for atopic dermatitis?

Featuring Peter Lio, MD

Atopic Dermatitis

What role can lebrikizumab play in steroid-sparing strategies for patients with atopic dermatitis?

Featuring Peter Lio, MD

Atopic Dermatitis

What are the current recommendations for the use of lebrikizumab in pediatric atopic dermatitis patients?

Featuring Peter Lio, MD

Atopic Dermatitis

Can patients treated with lebrikizumab receive live vaccines?

Featuring Peter Lio, MD

Atopic Dermatitis

What role does lebrikizumab play in managing chronic itch associated with atopic dermatitis?

Featuring Peter Lio, MD

Atopic Dermatitis

Can lebrikizumab be used with topical corticosteroids or topical calcineurin inhibitors?

Featuring Peter Lio, MD

Atopic Dermatitis

How can dermatologists differentiate atopic dermatitis from other eczematous conditions?

Featuring Peter Lio, MD

Atopic Dermatitis

What role does the skin microbiome play in the development and management of atopic dermatitis?

Featuring Peter Lio, MD

Atopic Dermatitis

How can dermatologists help patients manage the psychosocial impact of atopic dermatitis, including anxiety and depression?

Featuring Peter Lio, MD

Psoriasis

What are the most common side effects associated with ixekizumab in long-term use?

Featuring Laura Ferris, MD, PhD

Psoriasis

How does ixekizumab's mechanism of action differ from that of other biologics used for psoriasis?

Featuring Laura Ferris, MD, PhD

Psoriasis

How does the recommended dosing regimen for ixekizumab compare to those of other biologics for psoriasis?

Featuring Laura Ferris, MD, PhD

Psoriasis

Can ixekizumab be used in combination with topical treatments, and if so, what is the recommended approach?

Featuring Laura Ferris, MD, PhD

Psoriasis

Is there a need for loading doses when initiating ixekizumab therapy?

Featuring Laura Ferris, MD, PhD

Psoriasis

How should dermatologists approach ixekizumab therapy in patients planning to conceive?

Featuring Laura Ferris, MD, PhD

Psoriasis

What considerations should be made for elderly patients starting ixekizumab?

Featuring Laura Ferris, MD, PhD

Psoriasis

What are the considerations for using ixekizumab in patients with comorbidities such as diabetes or cardiovascular disease?

Featuring Laura Ferris, MD, PhD

Psoriasis

How should dermatologists address concerns about injection-site reactions in patients starting ixekizumab?

Featuring Laura Ferris, MD, PhD

Psoriasis

How should psoriasis be managed in patients with a history of liver disease?

Featuring Laura Ferris, MD, PhD

Psoriasis

What monitoring is essential for patients on long-term systemic psoriasis therapies?

Featuring Laura Ferris, MD, PhD

Psoriasis

What strategies can be used to improve patient adherence in psoriasis treatment regimens?

Featuring Laura Ferris, MD, PhD

Alopecia

What distinguishes the MOA of ritlecitinib from other JAK inhibitors?

Featuring Charlie Dunn, MD

Alopecia

Does patient age impact the effectiveness and safety of ritlecitinib?

Featuring Charlie Dunn, MD

Alopecia

How should patients be educated about the potential long-term outcomes of ritlecitinib therapy?

Featuring Charlie Dunn, MD

Alopecia

How soon can patients with alopecia areata begin to see results on ritlecitinib?

Featuring Charlie Dunn, MD

Alopecia

How does ritlecitinib perform in patients with severe alopecia areata?

Featuring Charlie Dunn, MD

Alopecia

What lab assessments are recommended prior to initiating ritlecitinib?

Featuring Charlie Dunn, MD

Alopecia

What are the most common adverse reactions seen with ritlecitinib?

Featuring Charlie Dunn, MD

Alopecia

What are some early signs and symptoms associated with alopecia areata?

Featuring Charlie Dunn, MD

Alopecia

Can dietary changes, lifestyle modifications, or supplements influence the course of alopecia areata?

Featuring Charlie Dunn, MD

Alopecia

How does the presence of comorbidities influence the management of alopecia areata?

Featuring Charlie Dunn, MD

Psoriasis

How does the safety profile of ixekizumab compare to other IL-17 inhibitors?

Featuring Saakshi Khattri , MD

Psoriasis

How soon can patients on ixekizumab for psoriasis expect to see results?

Featuring Saakshi Khattri , MD

Psoriasis

Can ixekizumab be safely used in patients with comorbidities like hepatitis B or tuberculosis?

Featuring Saakshi Khattri , MD

Psoriasis

Who is the ideal patient for ixekizumab, and are there any notable exclusions?

Featuring Saakshi Khattri , MD

Psoriasis

What patient education points are important to convey to patients starting ixekizumab?

Featuring Saakshi Khattri , MD

Psoriasis

Are there any dose adjustments needed for patients with renal or hepatic impairment when using ixekizumab?

Featuring Saakshi Khattri , MD

Psoriasis

Are there any head-to-head studies comparing ixekizumab to other biologics?

Featuring Saakshi Khattri , MD

Psoriasis

Do patients with nail and scalp psoriasis have a greater risk of developing psoriatic arthritis?

Featuring Saakshi Khattri , MD

Psoriasis

What are the most important factors to consider when selecting a first-line biologic for patients with psoriasis?

Featuring Saakshi Khattri , MD

Psoriasis

How do you manage patients with psoriasis with concurrent inflammatory bowel disease?

Featuring Saakshi Khattri , MD

Psoriasis

What are the most common adverse reactions seen with ixekizumab?

Featuring Raj Chovatiya, MD, PhD, MSCI

Psoriasis

What is the dosing regimen for ixekizumab?

Featuring Raj Chovatiya, MD, PhD, MSCI

Psoriasis

What factors should be considered when determining optimal treatment duration for ixekizumab in patients with psoriasis?

Featuring Raj Chovatiya, MD, PhD, MSCI

Psoriasis

Is ixekizumab safe for use in pediatric populations?

Featuring Raj Chovatiya, MD, PhD, MSCI

Psoriasis

What is the mechanism of action of ixekizumab?

Featuring Raj Chovatiya, MD, PhD, MSCI

Psoriasis

When do you consider a biologic as a first-line treatment for psoriasis?

Featuring Raj Chovatiya, MD, PhD, MSCI

Psoriasis

What are some common reasons for undertreatment of patients with psoriasis and how can dermatologists address this?

Featuring Raj Chovatiya, MD, PhD, MSCI

Psoriasis

What is your approach when counseling a patient who has experienced multiple treatment failures?

Featuring Raj Chovatiya, MD, PhD, MSCI

Psoriasis

What role does patient education play in improving adherence to psoriasis treatment regimens?

Featuring Raj Chovatiya, MD, PhD, MSCI

Psoriasis

How do newer biologic agents like IL-17 inhibitors compare to traditional biologics in psoriasis treatment?

Featuring Raj Chovatiya, MD, PhD, MSCI

Vitiligo

Can ruxolitinib be used as a first-line treatment for vitiligo?

Featuring Benjamin Lockshin, MD

Vitiligo

Can ruxolitinib be used with phototherapy

Featuring Benjamin Lockshin, MD

Vitiligo

What is your recommended approach for managing patients who do not respond to ruxolitinib therapy for vitiligo?

Featuring Benjamin Lockshin, MD

Vitiligo

How can you advise patients taking ruxolitinib for vitiligo on looking for signs of repigmentation

Featuring Benjamin Lockshin, MD

Vitiligo

How should you counsel patients about the risk of NMSC while using ruxolitinib for vitiligo?

Featuring Benjamin Lockshin, MD

Vitiligo

Are there any contraindications or precautions dermatologists should consider before beginning a patient on ruxolitinib for vitiligo?

Featuring Benjamin Lockshin, MD

Vitiligo

Is there any recommended monitoring for patients on ruxolitinib for vitiligo?

Featuring Benjamin Lockshin, MD

Vitiligo

Is phototherapy effective in all types of vitiligo?

Featuring Benjamin Lockshin, MD

Vitiligo

How soon should treatment be initiated after diagnosing vitiligo?

Featuring Benjamin Lockshin, MD

Vitiligo

What factors should be considered when selecting treatment for pediatric patients with vitiligo?

Featuring Benjamin Lockshin, MD

Vitiligo

Can ruxolitinib for vitiligo be used intermittently?

Featuring Cheri Frey, MD

Vitiligo

How can you advise patients taking ruxolitinib for vitiligo on looking for signs of repigmentation?

Featuring Cheri Frey, MD

Vitiligo

How does ruxolitinib compare to other treatment options for vitiligo?

Featuring Cheri Frey, MD

Vitiligo

Is there any risk of rebound or worsening of vitiligo symptoms after discontinuing ruxolitinib?

Featuring Cheri Frey, MD

Vitiligo

Are there any patient support programs available for ruxolitinib for vitiligo?

Featuring Cheri Frey, MD

Vitiligo

What factors should be considered when determining if a patient is eligible for ruxolitinib for vitiligo?

Featuring Cheri Frey, MD

Vitiligo

Can ruxolitinib be used with phototherapy?

Featuring Cheri Frey, MD

Vitiligo

What are some lesser-known comorbidities of vitiligo?

Featuring Cheri Frey, MD

Vitiligo

What is the outlook on regenerative therapies for vitiligo?

Featuring Cheri Frey, MD

Vitiligo

What are some triggers that may exacerbate vitiligo?

Featuring Cheri Frey, MD

Vitiligo

Can ruxolitinib for vitiligo be used on sensitive skin areas (David Rosmarin, MA, MD)?

Featuring David Rosmarin, MD

Vitiligo

What were the notable results of the TRuE-V1 and TRuE-V2 trials on ruxolitinib for vitiligo?

Featuring David Rosmarin, MD

Vitiligo

What results were seen in the 2-year open-label extension for ruxolitinib for vitiligo?

Featuring David Rosmarin, MD

Vitiligo

Should ruxolitinib be used as a monotherapy or can it be combined with other treatments for vitiligo?

Featuring David Rosmarin, MD

Vitiligo

How long should ruxolitinib treatment be continued for optimal results?

Featuring David Rosmarin, MD

Vitiligo

Which parts of the body does ruxolitinib work best on?

Featuring David Rosmarin, MD

Vitiligo

Are there any drug interactions to consider when prescribing ruxolitinib for vitiligo?

Featuring David Rosmarin, MD

Vitiligo

What are some important comorbidities associated with vitiligo?

Featuring David Rosmarin, MD

Vitiligo

How does ethnicity influence the presentation and management of vitiligo?

Featuring David Rosmarin, MD

Vitiligo

How do you counsel patients with vitiligo about the need for sun protection?

Featuring David Rosmarin, MD

Psoriasis

What is the recommended dosing regimen for tapinarof?

Featuring Tina Bhutani, MD, MAS

Psoriasis

Who is the ideal patient for tapinarof, and are there any notable exclusions?

Featuring Tina Bhutani, MD, MAS

Psoriasis

What is the safety profile of tapinarof?

Featuring Tina Bhutani, MD, MAS

Psoriasis

What is the mechanism of action of tapinarof?

Featuring Tina Bhutani, MD, MAS

Psoriasis

What should patients expect when they stop treatment with tapinarof?

Featuring Tina Bhutani, MD, MAS

Psoriasis

What were the primary endpoints of the PSOARING 1 and PSOARING 2 trials for tapinarof?

Featuring Tina Bhutani, MD, MAS

Psoriasis

Is tapinarof well tolerated on sensitive skin areas?

Featuring Tina Bhutani, MD, MAS

Psoriasis

What is the role of the Aryl hydrocarbon receptor in psoriasis and psoriasis management?

Featuring Tina Bhutani, MD, MAS

Psoriasis

What are the latest advancements in understanding the pathogenesis of psoriasis?

Featuring Tina Bhutani, MD, MAS

Psoriasis

How do lifestyle factors like diet and stress impact your approach to psoriasis management?

Featuring Tina Bhutani, MD, MAS

Psoriasis

How do you counsel patients on quality of life impacts from psoriasis?

Featuring Tina Bhutani, MD, MAS

Vitiligo

Who is the ideal patient for ruxolitinib for vitiligo?

Featuring Karan Lal, DO, MS, FAAD

Vitiligo

How do you set expectations with patients before starting them on ruxolitinib for vitiligo?

Featuring Karan Lal, DO, MS, FAAD

Vitiligo

How quickly can patients expect to see results with ruxolitinib for vitiligo?

Featuring Karan Lal, DO, MS, FAAD

Vitiligo

What is the safety profile of ruxolitinib for vitiligo?

Featuring Karan Lal, DO, MS, FAAD

Vitiligo

Can ruxolitinib for vitiligo be used with other JAK inhibitors?

Featuring Karan Lal, DO, MS, FAAD

Vitiligo

What are the limitations of use for ruxolitinib for vitiligo?

Featuring Karan Lal, DO, MS, FAAD

Vitiligo

What follow-up or monitoring do you recommend for patients on ruxolitinib for vitiligo?

Featuring Karan Lal, DO, MS, FAAD

Vitiligo

How does your treatment approach differ in treating segmental vs nonsegmental vitiligo?

Featuring Karan Lal, DO, MS, FAAD

Vitiligo

What is the role of the JAK-STAT pathway in vitiligo?

Featuring Karan Lal, DO, MS, FAAD

Vitiligo

How can dermatologists address challenges and disparities in access to vitiligo care?

Featuring Karan Lal, DO, MS, FAAD

Vitiligo

What is the mechanism of action for ruxolitinib for vitiligo?

Featuring Nicholas Brownstone, MD

Vitiligo

Why is there a boxed warning for ruxolitinib for vitiligo?

Featuring Nicholas Brownstone, MD

Vitiligo

What are the most common adverse reactions seen with ruxolitinib for vitiligo?

Featuring Nicholas Brownstone, MD

Vitiligo

What is the recommended dosing regimen for ruxolitinib for vitiligo?

Featuring Nicholas Brownstone, MD

Vitiligo

Can ruxolitinib for vitiligo be used on sensitive skin areas?

Featuring Nicholas Brownstone, MD

Vitiligo

What are some ways you set expectations with patients before starting them on ruxolitinib for vitiligo?

Featuring Nicholas Brownstone, MD

Vitiligo

Are there ways to treat vitiligo surgically?

Featuring Nicholas Brownstone, MD

Vitiligo

What long-term management strategies do you recommend for patients with vitiligo?

Featuring Nicholas Brownstone, MD

Vitiligo

How do you counsel patients with vitiligo on the dangers of unregulated skin lightening / bleaching creams?

Featuring Nicholas Brownstone, MD

Vitiligo

What is the psychosocial impact of vitiligo?

Featuring Nicholas Brownstone, MD

Psoriasis

What monitoring is recommended for routine patient management with bimekizumab to assess liver enzyme levels?

Featuring April Armstrong, MD, MPH

Psoriasis

How does the dosing regimen and speed of response of bimekizumab compare to other biologics for psoriasis?

Featuring April Armstrong, MD, MPH

Psoriasis

Is bimekizumab effective for patients who have failed an IL-17 blocker?

Featuring April Armstrong, MD, MPH

Psoriasis

Has the efficacy of bimekizumab been compared to other psoriasis medications?

Featuring April Armstrong, MD, MPH

Psoriasis

What is the long-term safety data for bimekizumab?

Featuring April Armstrong, MD, MPH

Psoriasis

What is the risk of suicidal ideation or behavior in patients taking bimekizumab?

Featuring April Armstrong, MD, MPH

Psoriasis

Does bimekizumab have a boxed warning?

Featuring April Armstrong, MD, MPH

Psoriasis

How do you approach long-term management of plaque psoriasis?

Featuring April Armstrong, MD, MPH

Psoriasis

What are some of the limitations of the current conventional clinical measures used to determine psoriasis severity?

Featuring April Armstrong, MD, MPH

Psoriasis

What are some limitations of the older biologics for psoriasis?

Featuring April Armstrong, MD, MPH

Warts And Molluscum

How is cantharidin applied?

Featuring Neal Bhatia, MD

Warts And Molluscum

On what areas of the body can cantharidin be applied?

Featuring Neal Bhatia, MD

Warts And Molluscum

What is the mechanism of action for cantharidin?

Featuring Neal Bhatia, MD

Warts And Molluscum

Can you reuse the cantharidin applicator?

Featuring Neal Bhatia, MD

Warts And Molluscum

Why is denatonium benzoate included in the ingredient list for cantharidin?

Featuring Neal Bhatia, MD

Warts And Molluscum

What are some important instructions you should give to give patients being treated with cantharidin?

Featuring Neal Bhatia, MD

Warts And Molluscum

Why are patients with atopic dermatitis more at risk of contracting molluscum contagiosum?

Featuring Neal Bhatia, MD

Warts And Molluscum

What are some complications and long-term effects associated with molluscum contagiosum?

Featuring Neal Bhatia, MD

Warts And Molluscum

What are some of the biggest challenges in treating molluscum contagiosum?

Featuring Neal Bhatia, MD

Skin Cancer

What classification from the 40-GEP test would make you consider referral to a radiation oncologist and adjuvant radiation therapy?

Featuring Laura Ferris, MD, PhD

Skin Cancer

Can the 40-GEP test be performed on superficial biopsies?

Featuring Laura Ferris, MD, PhD

Skin Cancer

How long does it take for a report to be delivered for the 40-GEP test?

Featuring Laura Ferris, MD, PhD

Skin Cancer

Do you consider imaging for patients with class 2a or 2b results on the 40-GEP test?

Featuring Laura Ferris, MD, PhD

Skin Cancer

How do accuracy metrics of the 40-GEP test compare with those of the AJCC8 and BWH?

Featuring Laura Ferris, MD, PhD

Skin Cancer

How does the 40-GEP test influence your decision to use radiologic imaging to check regional lymph nodes and distant organs for metastasis?

Featuring Laura Ferris, MD, PhD

Skin Cancer

What clinicopathologic factors have significant prognostic value?

Featuring Laura Ferris, MD, PhD

Skin Cancer

How do you undertake a multidisciplinary approach to SCC management?

Featuring Laura Ferris, MD, PhD

Skin Cancer

What patient and disease characteristics do you consider when choosing a systemic therapy for patients with metastatic SCC?

Featuring Laura Ferris, MD, PhD

Skin Cancer

How does the test inform the clinical management of patients with high-risk SCC?

Featuring Laura Ferris, MD, PhD

Psoriasis

Is there drug monitoring required for bimekizumab?

Featuring Mark Lebwohl, MD

Psoriasis

What is the dosing regimen for bimekizumab?

Featuring Mark Lebwohl, MD

Warts And Molluscum

Which patients are eligible for treatment with cantharidin, and are there any notable exclusions?

Featuring Latanya Benjamin, MD, FAAD, FAAP

Warts And Molluscum

What are some of the most common adverse reactions associated with cantharidin?

Featuring Latanya Benjamin, MD, FAAD, FAAP

Warts And Molluscum

Does cantharidin provide any benefits over other treatments for molluscum contagiosum?

Featuring Latanya Benjamin, MD, FAAD, FAAP

Warts And Molluscum

How does the cantharidin applicator work?

Featuring Latanya Benjamin, MD, FAAD, FAAP

Warts And Molluscum

Can other topical products be used after cantharidin application?

Featuring Latanya Benjamin, MD, FAAD, FAAP

Warts And Molluscum

What is the recommended dosing regimen for cantharidin?

Featuring Latanya Benjamin, MD, FAAD, FAAP

Warts And Molluscum

What were the primary endpoints of the CAMP-1 and CAMP-2 trials?

Featuring Latanya Benjamin, MD, FAAD, FAAP

Warts And Molluscum

What are some interesting facets of the pathophysiology of molluscum contagiosum?

Featuring Latanya Benjamin, MD, FAAD, FAAP

Warts And Molluscum

How do you navigate concerns from parents of pediatric patients with molluscum contagiosum?

Featuring Latanya Benjamin, MD, FAAD, FAAP

Warts And Molluscum

Which patients are at higher risk of contracting molluscum contagiosum?

Featuring Latanya Benjamin, MD, FAAD, FAAP

Psoriasis

What is the mechanism of action of bimekizumab and how does it differ from other systemic psoriasis treatments?

Featuring Mark Lebwohl, MD

Psoriasis

What is the safety profile of bimekizumab and what are the most common adverse effects seen so far?

Featuring Mark Lebwohl, MD

Psoriasis

Who is eligible for treatment with bimekizumab? Are there any notable exclusion criteria?

Featuring Mark Lebwohl, MD

Atopic Dermatitis

What is the mechanism of action for ruxolitinib topical cream?

Featuring Linda Stein Gold, MD

Atopic Dermatitis

What strategies can you use to improve adherence with ruxolitinib?

Featuring Linda Stein Gold, MD

Atopic Dermatitis

What is the benefit of ruxolitinib over topical calcineurin inhibitors?

Featuring Linda Stein Gold, MD

Atopic Dermatitis

What is the benefit of ruxolitinib over topical corticosteroids?

Featuring Linda Stein Gold, MD

Atopic Dermatitis

What is the benefit of ruxolitinib over topical PDE-4 inhibitors?

Featuring Linda Stein Gold, MD

Atopic Dermatitis

Can ruxolitinib be used intermittently as maintenance to reduce flares and relapse?

Featuring Linda Stein Gold, MD

Atopic Dermatitis

What were the notable results of the TRuE-AD clinical trials for topical ruxolitinib?

Featuring Linda Stein Gold, MD

Atopic Dermatitis

What are some considerations when diagnosing and treating atopic dermatitis in patients with skin of color?

Featuring Linda Stein Gold, MD

Atopic Dermatitis

What are some of the unmet needs still remaining in the atopic dermatitis treatment landscape?

Featuring Linda Stein Gold, MD

Atopic Dermatitis

What maintenance therapy for atopic dermatitis do you recommend to patients?

Featuring Linda Stein Gold, MD

Psoriasis

What is the recommended dosing regimen for clobetasol propionate cream 0.025%?

Featuring Leon Kircik, MD

Psoriasis

How does the safety and efficacy of clobetasol propionate cream 0.025% compare with the 0.05% cream?

Featuring Leon Kircik, MD

Psoriasis

What makes the formulation of clobetasol propionate cream 0.025% unique?

Featuring Leon Kircik, MD

Psoriasis

What is the recommended dosing regimen for betamethasone dipropionate spray 0.05%?

Featuring Leon Kircik, MD

Psoriasis

What are some of the benefits of a spray treatment like betamethasone dipropionate spray 0.05% for plaque psoriasis?

Featuring Leon Kircik, MD

Psoriasis

What areas of the body does betamethasone dipropionate spray 0.05% work best on?

Featuring Leon Kircik, MD

Psoriasis

How important is the delivery vehicle when selecting a topical treatment for psoriasis?

Featuring Leon Kircik, MD

Psoriasis

How do you counsel patients on the importance of adherence when prescribing a topical treatment for psoriasis?

Featuring Leon Kircik, MD

Psoriasis

Do issues of accessibility affect your approach when considering treatment options for plaque psoriasis?

Featuring Leon Kircik, MD

Psoriasis

What place do topicals have in the psoriasis treatment landscape now that the range of therapeutic options has expanded dramatically?

Featuring Leon Kircik, MD

Psoriasis

How do you foresee the availability of nonsteroidal topical options contributing to the standard of care for plaque psoriasis?

Featuring Jennifer Soung, MD

Psoriasis

What are some of the limitations of topical steroids with respect to management of plaque psoriasis?

Featuring Jennifer Soung, MD

Psoriasis

What are important considerations when treating plaque psoriasis in sensitive areas such as the face, folds, and genitals?

Featuring Jennifer Soung, MD

Psoriasis

What limitations of other topical therapies does roflumilast address for patients with plaque psoriasis?

Featuring Jennifer Soung, MD

Psoriasis

What clinical findings strike you most when choosing topical roflumilast for patients with plaque psoriasis?

Featuring Jennifer Soung, MD

Psoriasis

Can you explain the significance of roflumilast’s indication being inclusive of intertriginous areas with plaque psoriasis?

Featuring Jennifer Soung, MD

Psoriasis

Can topical roflumilast be used in combination with systemic therapies?

Featuring Jennifer Soung, MD

Psoriasis

Is topical roflumilast safe and effective for long-term use?

Featuring Jennifer Soung, MD

Psoriasis

How would you describe the formulation/vehicle for topical roflumilast?

Featuring Jennifer Soung, MD

Psoriasis

Now that there are more options to treat psoriasis, how do you choose when to use roflumilast?

Featuring Jennifer Soung, MD

Psoriasis

What is new and exciting for treating pediatric patients with plaque psoriasis?

Featuring Jennifer Soung, MD

Psoriasis

With all of the new treatments for psoriasis that have been approved in recent years, is there still an unmet need?

Featuring Mark Lebwohl, MD

Psoriasis

Can you speak to the efficacy of bimekizumab from the three pivotal head-to-head trials?

Featuring Mark Lebwohl, MD

Psoriasis

How quickly does bimekizumab start working?

Featuring Mark Lebwohl, MD

Psoriasis

Regarding oral candidiasis, how has this been managed and has it required discontinuation of the medication?

Featuring Mark Lebwohl, MD

Psoriasis

Are there any support programs to help patients access bimekizumab?

Featuring Mark Lebwohl, MD

Alopecia

Is baricitinib effective for patients with substantial eyebrow and eyelash loss?

Featuring James Del Rosso, DO

Alopecia

Are there any support programs available for patients who are prescribed baricitinib?

Featuring James Del Rosso, DO

Alopecia

Can baricitinib be used in combination with topical treatments?

Featuring James Del Rosso, DO

Alopecia

How does the efficacy of baricitinib compare to topical and corticosteroid treatments?

Featuring James Del Rosso, DO

Alopecia

What was the primary measure of efficacy in the 2 randomized double-blind clinical trials conducted on baricitinib?

Featuring James Del Rosso, DO

Alopecia

What was the baseline SALT score for patients included in the BRAVE-AA1 and BRAVE-AA2 trials?

Featuring James Del Rosso, DO

Alopecia

When is baricitinib recommended for atopic dermatitis?

Featuring James Del Rosso, DO

Alopecia

Should baricitinib dosage be reduced when adequate response is achieved?

Featuring James Del Rosso, DO

Alopecia

Are results maintained after lowering the dosage or stoppage of baricitinib?

Featuring James Del Rosso, DO

Alopecia

Is long-term treatment necessary to observe maximal clinical benefit from baricitinib?

Featuring James Del Rosso, DO

Alopecia

What kind of monitoring is suggested for patients taking baricitinib?

Featuring James Del Rosso, DO

Generalized Pustular Psoriasis (GPP)

Which patients are recommended for treatment with spesolimab, and are there any exclusions?

Featuring Brad Glick, DO, MPH

Generalized Pustular Psoriasis (GPP)

What spesolimab-associated hypersensitivity reactions should patients be monitored for?

Featuring Brad Glick, DO, MPH

Generalized Pustular Psoriasis (GPP)

Can patients treated with spesolimab receive live vaccines?

Featuring Brad Glick, DO, MPH

Generalized Pustular Psoriasis (GPP)

What is the recommended dosing regimen for spesolimab?

Featuring Brad Glick, DO, MPH

Generalized Pustular Psoriasis (GPP)

What is the mechanism of action of spesolimab?

Featuring Brad Glick, DO, MPH

Generalized Pustular Psoriasis (GPP)

How quickly can patients see the onset of pustular clearance after a spesolimab infusion? 

Featuring Brad Glick, DO, MPH

Generalized Pustular Psoriasis (GPP)

What was the primary endpoint of the Effasayil trial?

Featuring Brad Glick, DO, MPH

Generalized Pustular Psoriasis (GPP)

The use, tapering, or stopping of which medications can be associated with GPP?

Featuring Brad Glick, DO, MPH

Generalized Pustular Psoriasis (GPP)

What are some lesser-known risk factors of GPP?

Featuring Brad Glick, DO, MPH

Generalized Pustular Psoriasis (GPP)

What are some of the biggest challenges in treating GPP?

Featuring Brad Glick, DO, MPH

Psoriasis

What are some patient examples you’ve had success with using topical roflumilast?

Featuring Saakshi Khattri , MD

Psoriasis

How does the formulation of roflumilast differ from other topicals?

Featuring Saakshi Khattri , MD

Psoriasis

What properties of roflumilast allow it to follow a once-daily dosing regimen?

Featuring Saakshi Khattri , MD

Psoriasis

What is the mechanism of action of roflumilast?

Featuring Saakshi Khattri , MD

Psoriasis

Do patients using roflumilast experience stinging and burning?

Featuring Saakshi Khattri , MD

Psoriasis

Are there any limitations on duration of use with roflumilast?

Featuring Saakshi Khattri , MD

Psoriasis

Who is the ideal patient for roflumilast?

Featuring Saakshi Khattri , MD

Psoriasis

What does the long-term safety and durability profile look like for roflumilast?

Featuring Saakshi Khattri , MD

Psoriasis

Does roflumilast continue to be effective over a long period of time?

Featuring Saakshi Khattri , MD

Psoriasis

Has the emergence of new topical options affected the course of treatment you select for your patients?

Featuring Saakshi Khattri , MD

Psoriasis

What are the advantages of topical therapy as monotherapy over systemic therapy for plaque psoriasis?  

Featuring Saakshi Khattri , MD

Psoriasis

How have the emergence of nonsteroidal topical options in recent years impacted your practice?

Featuring Saakshi Khattri , MD

Skin Cancer

How do you foresee the 40-GEP test contributing to standard of care for SCC?

Featuring Steven Eilers, MD

Skin Cancer

What risk factors relating to history and physical examination would make a patient with SCC a good candidate for the 40-GEP test?

Featuring Steven Eilers, MD

Skin Cancer

What surgical and pathological findings would make a patient with SCC a good candidate for the 40-GEP test?

Featuring Steven Eilers, MD

Skin Cancer

Is an additional procedure needed to collect a specimen for the 40-GEP test?

Featuring Steven Eilers, MD

Skin Cancer

What classification from the 40-GEP test would make you consider baseline radiologic imaging?

Featuring Steven Eilers, MD

Skin Cancer

What classification from the 40-GEP test would make you consider sentinel lymph node biopsy?

Featuring Steven Eilers, MD

Skin Cancer

Are there any patient access programs available for the 40-GEP test?

Featuring Steven Eilers, MD

Skin Cancer

Which class is the best predictor of metastasis with regard to the 40-GEP test?

Featuring Steven Eilers, MD

Skin Cancer

What are some lesser-known factors that can increase the risk of developing SCC?

Featuring Steven Eilers, MD

Skin Cancer

How can we better educate our patients on minimizing the risk of developing SCC?

Featuring Steven Eilers, MD

Skin Cancer

What is the connection between calcineurin inhibitors and SCC development and progression?

Featuring Steven Eilers, MD

Skin Cancer

Why do organ transplant recipients have a higher risk of developing SCC?

Featuring Steven Eilers, MD

Skin Cancer

What is the 40-GEP test?

Featuring Darrell Rigel, MD, MS

Alopecia

In what ways can alopecia areata affect quality of life?

Featuring Michael Cameron, MD

Atopic Dermatitis

How can I identify patients who would benefit from ruxolitinib cream?

Featuring Raj Chovatiya, MD, PhD, MSCI

Generalized Pustular Psoriasis (GPP)

What is the clinical presentation of GPP?

Featuring Erin Boh, MD, PhD

Skin Cancer

Why do we need to better assess SCC prognosis?

Featuring Darrell Rigel, MD, MS

Skin Cancer

How does the 40-GEP test work?

Featuring Darrell Rigel, MD, MS

Skin Cancer

What SCCs are appropriate for the 40-GEP test?

Featuring Darrell Rigel, MD, MS

Skin Cancer

How do you discuss 40-GEP test results with patients?

Featuring Darrell Rigel, MD, MS

Skin Cancer

Is the 40-GEP test covered by Medicare?

Featuring Darrell Rigel, MD, MS

Skin Cancer

Why doesn't SCC get the respect it should?

Featuring Darrell Rigel, MD, MS

Skin Cancer

What are the traditional SCC prognostic paradigms?

Featuring Darrell Rigel, MD, MS

Skin Cancer

What are the trends in US incidence of SCC?

Featuring Darrell Rigel, MD, MS

Skin Cancer

Who is the ideal patient for the 40-GEP test?

Featuring Darrell Rigel, MD, MS

Alopecia

Are patients with alopecia areata more likely to have other dermatologic conditions?

Featuring Michael Cameron, MD

Alopecia

What was the ORAL Surveillance study, and how does it relate to the labeling language of Olumiant?

Featuring Michael Cameron, MD

Alopecia

Which patients are eligible for treatment with baricitinib and are there any notable exclusion criteria?

Featuring Michael Cameron, MD

Alopecia

How soon can patients start seeing results on baricitinib?

Featuring Michael Cameron, MD

Alopecia

What is the mechanism of action of baricitinib?

Featuring Michael Cameron, MD

Alopecia

How does the mechanism of action of baricitinib differ from topical JAK inhibitors?

Featuring Michael Cameron, MD

Alopecia

Can baricitinib be used in combination with other biologics, JAK inhibitors, or immunosuppressants?

Featuring Michael Cameron, MD

Alopecia

What is the recommended dosing regimen for baricitinib?

Featuring Michael Cameron, MD

Alopecia

Is there any long-term safety data available for baricitinib?

Featuring Michael Cameron, MD

Atopic Dermatitis

Can ruxolitinib cream be used in combination with therapeutic biologics, other JAK inhibitors, or immunosuppressants?

Featuring Raj Chovatiya, MD, PhD, MSCI

Atopic Dermatitis

What limitations of other atopic dermatitis therapies does ruxolitinib cream address?

Featuring Raj Chovatiya, MD, PhD, MSCI

Atopic Dermatitis

How quickly can patients expect to start feeling itch reduction with ruxolitinib cream?

Featuring Raj Chovatiya, MD, PhD, MSCI

Atopic Dermatitis

Ruxolitinib cream is indicated for short-term use; when should patients discontinue use?

Featuring Raj Chovatiya, MD, PhD, MSCI

Atopic Dermatitis

What is the recommended dosing regimen for ruxolitinib cream?

Featuring Raj Chovatiya, MD, PhD, MSCI

Atopic Dermatitis

What is the maximum dosage per week recommended for ruxolitinib cream?

Featuring Raj Chovatiya, MD, PhD, MSCI

Atopic Dermatitis

When do you recommend the use of wet wrap therapy for patients with atopic dermatitis experiencing a flare?

Featuring Raj Chovatiya, MD, PhD, MSCI

Atopic Dermatitis

When should oral antibiotics be used in the treatment of atopic dermatitis?

Featuring Raj Chovatiya, MD, PhD, MSCI

Atopic Dermatitis

What do you recommend for patients with atopic dermatitis who require long-term treatment?

Featuring Raj Chovatiya, MD, PhD, MSCI

JAK Inhibitors

Are IL-23 blockers as effective as TNF and IL-17 blockers at preventing the progression of PsA?

Featuring Brad Glick, DO, MPH

JAK Inhibitors

If a patient is on long term prednisone from PCP for refractory AD can that patient also start a JAK?

Featuring Brad Glick, DO, MPH

JAK Inhibitors

Any concern using topical JAK inhibitors in patients on dupilumab?

Featuring Brad Glick, DO, MPH

JAK Inhibitors

Do new topicals address underlying systemic inflammation?

Featuring Brad Glick, DO, MPH

JAK Inhibitors

Do you check baseline or intermittent labs on dupilumab or tralokinumab for AD?

Featuring Brad Glick, DO, MPH

JAK Inhibitors

Do you recommend getting the zoster vaccine before starting a JAK inhibitor?

Featuring Brad Glick, DO, MPH

JAK Inhibitors

Can tapinarof be used in pregnant patients with psoriasis?

Featuring Brad Glick, DO, MPH

JAK Inhibitors

Roflumilast vs tapinarof - which is more efficacious?

Featuring Brad Glick, DO, MPH

JAK Inhibitors

What is the best treatment for lichen planus pigmentosus?

Featuring Brad Glick, DO, MPH

Skin Cancer

How has the 40-GEP test been used by my colleagues?

Featuring Aaron Farberg, MD

Atopic Dermatitis

What is the success rate of tralokinumab in patients who have failed dupilumab?

Featuring Tina Bhutani, MD, MAS

Psoriasis

How quickly do patients experience clearance results with topical roflumilast?

Featuring Peter Lio, MD

Psoriasis

How would you describe the overall tolerability of topical roflumilast?

Featuring Peter Lio, MD

Psoriasis

What is the long-term safety and efficacy data of topical roflumilast? 

Featuring Peter Lio, MD

Psoriasis

How has topical roflumilast simplified the way you consult patients with plaque psoriasis?

Featuring Peter Lio, MD

Psoriasis

How would you present the product profile of topical roflumilast to HCP colleagues who are reluctant due to poor prior experience with other PDE4 inhibitors?

Featuring Peter Lio, MD

Psoriasis

When it comes to treating thicker plaques on hands and feet, why should you consider Zoryve instead of steroids?

Featuring Peter Lio, MD

Psoriasis

What are your thoughts on topical roflumilast as becoming standard of care and gradual shifting away from topical corticosteroids?

Featuring Peter Lio, MD

Psoriasis

How do you approach management of plaque psoriasis in challenging sensitive areas?

Featuring Peter Lio, MD

Psoriasis

How important is inclusion of younger ages - adolescent or pediatric – when it comes to indication for plaque psoriasis treatments?

Featuring Peter Lio, MD

Psoriasis

When augmenting oral and/or biologic therapy with a topical, what are some of the considerations you think through?

Featuring Peter Lio, MD

Generalized Pustular Psoriasis (GPP)

What is Generalized Pustular Psoriasis (GPP)?

Featuring Erin Boh, MD, PhD

Generalized Pustular Psoriasis (GPP)

What are some of the systemic associations of acute GPP?

Featuring Erin Boh, MD, PhD

Generalized Pustular Psoriasis (GPP)

Who is at risk for GPP?

Featuring Erin Boh, MD, PhD

Generalized Pustular Psoriasis (GPP)

What are some known triggers of GPP?

Featuring Erin Boh, MD, PhD

Generalized Pustular Psoriasis (GPP)

What is the pathophysiology of GPP?

Featuring Erin Boh, MD, PhD

Generalized Pustular Psoriasis (GPP)

How does the pathophysiology in GPP differ from plaque type psoriasis?

Featuring Erin Boh, MD, PhD

Generalized Pustular Psoriasis (GPP)

When evaluating a patient with suspected GPP, what other entities does one need to exclude?

Featuring Erin Boh, MD, PhD

Generalized Pustular Psoriasis (GPP)

What are some of the common laboratory abnormalities associated with GPP?

Featuring Erin Boh, MD, PhD

Generalized Pustular Psoriasis (GPP)

What are treatment options for GPP?

Featuring Erin Boh, MD, PhD

Generalized Pustular Psoriasis (GPP)

What is the safety profile for spesolimab?

Featuring Erin Boh, MD, PhD

Psoriasis

What ingredients do you like to see in the products you use to treat plaque psoriasis?

Featuring Joseph Pietrangelo, MD

Psoriasis

How important are vehicles in topical Plaque Psoriasis therapy? 

Featuring Joseph Pietrangelo, MD

Psoriasis

What common ingredients in topical therapies for plaque psoriasis may cause irritation for your patients?

Featuring Joseph Pietrangelo, MD

Psoriasis

Should we really care about systemic safety when treating Plaque Psoriasis with topical therapies? 

Featuring Joseph Pietrangelo, MD

Psoriasis

How important is continuity of care for topical plaque psoriasis therapy? 

Featuring Joseph Pietrangelo, MD

Psoriasis

How much time does your staff have to spend gaining patient access to medication for plaque psoriasis? 

Featuring Joseph Pietrangelo, MD

Psoriasis

How do you utilize product samples in plaque psoriasis? 

Featuring Joseph Pietrangelo, MD

Psoriasis

How do access, tolerability and efficacy improve compliance? 

Featuring Joseph Pietrangelo, MD

Psoriasis

Which patients fit the profile for combination therapy of Biologics and topical treatment in Plaque Psoriasis?

Featuring Joseph Pietrangelo, MD

Psoriasis

How do you address compliance with your patients in topical treatment of plaque psoriasis?

Featuring Joseph Pietrangelo, MD

Skin Cancer

What are high risk features of cSCC?

Featuring Aaron Farberg, MD

Skin Cancer

What is the best sunscreen to prevent skin cancer?

Featuring Aaron Farberg, MD

Skin Cancer

Is SCC more deadly than melanoma?

Featuring Aaron Farberg, MD

Skin Cancer

How do I order the 40-GEP test?

Featuring Aaron Farberg, MD

Skin Cancer

Should I consider the 40-GEP test in lower risk patients?

Featuring Aaron Farberg, MD

Skin Cancer

Which patients should be considered for the 40-GEP test?

Featuring Aaron Farberg, MD

Skin Cancer

Why has the 40-GEP test been validated on several data sets?

Featuring Aaron Farberg, MD

Skin Cancer

How was the 40-GEP test developed?

Featuring Aaron Farberg, MD

Skin Cancer

How do GEP tests work?

Featuring Aaron Farberg, MD

Aesthetics

Why should you consider treating the chin with fillers when considering lip augmentation?

Featuring Gabriela Maloney, DO

Aesthetics

Botox for the neck: where do you start and how many units do you recommend?

Featuring Gabriela Maloney, DO

What leads to burnout, and what can we do to help deal with it?

Featuring Mark Kaufmann, MD

What do we need to know about telederm?

Featuring Mark Kaufmann, MD

What advice would you give a young dermatologist who wants to get involved in leadership in our specialty?

Featuring Mark Kaufmann, MD

In your opinion, what is the most worrisome trend in Healthcare?

Featuring Mark Kaufmann, MD

What is Camp Discovery, and how can I get involved?

Featuring Mark Kaufmann, MD

What are the advocacy priorities of the AAD?

Featuring Mark Kaufmann, MD

How are PBMs and Health insurance companies related to one another?

Featuring Mark Kaufmann, MD

What is Sequestration, when can we expect it to end?

Featuring Mark Kaufmann, MD

What is Budget neutrality, and how does it affect our reimbursement?

Featuring Mark Kaufmann, MD

How do I get involved with the AAD?

Featuring Mark Kaufmann, MD

Atopic Dermatitis

What is the role of diet and environment in the pathogenesis of AD?

Featuring Tina Bhutani, MD, MAS

Atopic Dermatitis

Do you recommend getting a CBC before using topical ruxolitinib in patients with a history of thrombocytopenia, anemia or neutropenia?

Featuring Tina Bhutani, MD, MAS

Atopic Dermatitis

Are there any complementary and alternative therapies which have data showing efficacy in the treatment of AD?

Featuring Tina Bhutani, MD, MAS

Atopic Dermatitis

Is it appropriate to reduce the frequency of tralokinumab in patients who respond to the medication?

Featuring Tina Bhutani, MD, MAS

Atopic Dermatitis

Does tralokinumab have a higher rate of conjunctivitis versus dupilumab?

Featuring Tina Bhutani, MD, MAS

Atopic Dermatitis

Does topical ruxolitinib work for pruritus or pruritic disorders?

Featuring Tina Bhutani, MD, MAS

Atopic Dermatitis

Is topical ruxolitinib safe for use on the face, armpit or groin?

Featuring Tina Bhutani, MD, MAS

Atopic Dermatitis

Is topical ruxolitinib still effective if only used once a day for atopic dermatitis?

Featuring Tina Bhutani, MD, MAS

Atopic Dermatitis

Should you perform total body skin exams on patients to screen for skin cancer in patients using topical ruxolitinib?

Featuring Tina Bhutani, MD, MAS

Atopic Dermatitis

Are there differences in the genetic risk factors for atopic dermatitis in Skin of Color patients?

Featuring Susan Taylor, MD

Load more videos

648 of 900